抗血小板-质子抑制剂相互作用和动脉血栓事件:使用不成比例和相互作用分析进行药监测评估
1Department of Pharmacology &p Therapeutics, College of Medicine & Health Sciences, Arabian Gulf University, Manama, Kingdom of Bahrain.
Current cardiology reviews
|May 13, 2025
概括
这项研究发现了 klopidogrel-rabeprazole 和 klopidogrel-omeprazole 组合的安全问题. 将阿司匹林添加到与质子抑制剂 (PPI) 的双抗血小板治疗 (DAPT) 中,可能会减少血栓栓塞事件.
科学领域:
- 药物监督 药物监督 药物监督
- 药品安全 药品安全
- 心血管医学 心血管医学
背景情况:
- 与抗血小板治疗同时使用质子抑制剂 (PPI) 是有争议的.
- 人们对PPI对抗血小板功效的影响存在担忧,特别是双抗血小板疗法 (DAPT).
研究的目的:
- 评估抗血小板-PPI组合的安全性.
- 评估同时使用抗血小板-PPI的临床影响.
- 为了比较抗血小板-PPI组合的血栓栓塞风险概况.
主要方法:
- 对FDA不良事件报告系统 (FAERS) 数据库的分析.
- 报告概率比率 (ROR) 和安全信号的信息组件的计算.
- 使用相互作用信号评分 (INTSS) 来评估添加阿司匹林到克洛皮多格雷尔-PPI组合的效果.
主要成果:
- 用克洛皮多格雷尔-拉贝普拉和克洛皮多格雷尔-奥梅普拉进行血栓栓塞事件的显著安全信号.
- DAPT-PPI组合显示出与单疗法-PPI组合相比的安全性.
- INTSS建议阿司匹林在克洛皮多格雷尔-PPI组合中具有潜在的保护作用.
结论:
- DAPT-PPI组合具有可接受的安全性概况,但PPI选择需要仔细考虑 (rabeprazole和omeprazole标记).
- 除了阿司匹林和克洛皮多格雷尔-PPI组合,阿司匹林还可以提供血栓栓塞的保护.
- 在选择抗血小板-PPI组合时,个性化风险益处评估至关重要.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
396
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
396
Pharmacovigilance
748
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
748
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
108
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
108
Anticoagulant Drugs: Low-Molecular-Weight Heparins
548
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
548
Factors Affecting Protein-Drug Binding: Drug Interactions
67
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
67
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.0K


